NO20090628L - Pyridizinon derivativater - Google Patents

Pyridizinon derivativater

Info

Publication number
NO20090628L
NO20090628L NO20090628A NO20090628A NO20090628L NO 20090628 L NO20090628 L NO 20090628L NO 20090628 A NO20090628 A NO 20090628A NO 20090628 A NO20090628 A NO 20090628A NO 20090628 L NO20090628 L NO 20090628L
Authority
NO
Norway
Prior art keywords
pyridizinone
derivatives
pyridizinone derivatives
inhibitors
processes
Prior art date
Application number
NO20090628A
Other languages
English (en)
Inventor
Ming Tao
Allison L Zulli
Nadine C Becknell
Greg Hostetler
Robert L Hudkins
Kurt A Josef
Lars J S Knutson
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20090628L publication Critical patent/NO20090628L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer forbindelser med formel (I*): ; I* deres anvendelse som H3 inhibitorer, prosesser for deres fremstilling og farmasøytiske preparater derav.
NO20090628A 2006-07-25 2009-02-10 Pyridizinon derivativater NO20090628L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83316406P 2006-07-25 2006-07-25
PCT/US2007/016699 WO2008013838A2 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives

Publications (1)

Publication Number Publication Date
NO20090628L true NO20090628L (no) 2009-04-21

Family

ID=38857882

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090628A NO20090628L (no) 2006-07-25 2009-02-10 Pyridizinon derivativater

Country Status (24)

Country Link
US (5) US8247414B2 (no)
EP (3) EP2502918B1 (no)
JP (1) JP5335675B2 (no)
KR (2) KR20140037967A (no)
CN (1) CN101522638B (no)
AU (1) AU2007277163B2 (no)
BR (1) BRPI0713836A2 (no)
CA (2) CA2658821C (no)
DK (1) DK2069312T3 (no)
EA (1) EA017004B1 (no)
ES (1) ES2397283T3 (no)
HR (1) HRP20130044T1 (no)
IL (1) IL196543A (no)
MX (1) MX2009000884A (no)
MY (1) MY148634A (no)
NO (1) NO20090628L (no)
NZ (1) NZ574873A (no)
PL (1) PL2069312T3 (no)
PT (1) PT2069312E (no)
RS (1) RS52626B (no)
SI (1) SI2069312T1 (no)
UA (1) UA95644C2 (no)
WO (1) WO2008013838A2 (no)
ZA (1) ZA200901336B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038439B2 (ja) 1989-12-28 2000-05-08 昭和電工株式会社 複合ダイヤモンド粒を用いた切削、研削、研摩具
US5241062A (en) * 1993-01-19 1993-08-31 Sun Company, Inc. (R&M) Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0712823A2 (pt) * 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
BRPI0810330A2 (pt) 2007-05-03 2014-10-14 Cephalon Inc "processo para preparar l-tartarato de (r)-2-metil pirrolidina, processo para preparar 6-{4-[3-((r)-2-metil-pirrolidin-1-il)-propoxi] - fenil}-2h-piridazin-3-ona, processo para preparar d-tartarato de (s)-2-metil pirrolidina"
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2752406A1 (en) 2008-01-30 2014-07-09 Cephalon, Inc. Substituted pyridazine derivatives which have histamine H3 antagonist activity
WO2009142732A2 (en) * 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011002984A1 (en) * 2009-07-02 2011-01-06 Cephalon, Inc. Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
KR101303283B1 (ko) * 2011-03-28 2013-09-04 한국화학연구원 피리다지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
AU2012382373A1 (en) * 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
JP6417402B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
CN103772352B (zh) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR102354068B1 (ko) 2016-03-30 2022-01-25 이시하라 산교 가부시끼가이샤 피리다지논계 화합물 또는 그의 염, 및 그것들을 함유하는 제초제
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
CN109476639B (zh) * 2016-07-22 2021-02-26 橘生药品工业股份有限公司 吡咯烷衍生物
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
CN109111400B (zh) * 2017-06-23 2020-10-16 杭州百诚医药科技股份有限公司 苯基喹啉酮类和黄酮类衍生物的制备和应用
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
CN108264488A (zh) * 2018-01-26 2018-07-10 天津瑞岭化工有限公司 一种取代2,3-二氮杂萘酮类化合物的制备方法
EP3746079A1 (en) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
MA71645A (fr) 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
ES2958954T3 (es) 2018-11-06 2024-02-16 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de los mismos
EP3877052B1 (en) 2018-11-06 2023-08-16 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
WO2020157199A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
US12576033B2 (en) 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
GB201917101D0 (en) 2019-11-25 2020-01-08 Uea Enterprises Ltd Method for digesting nucleic acid in a sample
JP7758687B2 (ja) * 2020-05-13 2025-10-22 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋疾患の処置のためのピリダジノン化合物
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
CN114560814B (zh) * 2022-03-02 2023-10-20 天津理工大学 一种取代2,3-二氮杂萘酮类化合物的合成方法
CN121816184A (zh) * 2023-11-07 2026-04-07 傲拓神经科学公司 作为单一疗法或与抗精神病药剂组合使用伊达吡生来治疗伴有明显快感缺失的患者的精神或神经障碍

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011321A (en) * 1973-12-19 1977-03-08 Smith Kline & French Laboratories Limited Pharmaceutical compositions and methods of inhibiting β-adrenergic receptors
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
IE42214B1 (en) * 1974-06-18 1980-07-02 Smith Kline French Lab Hydrazinopyredazines
US4111936A (en) * 1974-06-18 1978-09-05 Smith Kline & French Laboratories Limited Pyridazinethiones
US4111935A (en) * 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
US4082843A (en) * 1975-11-26 1978-04-04 Smith Kline & French Laboratories Limited 3-(3-(3-Substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines and their use as vasodilators and β-adrenergic blocking agents
BE836633A (fr) 1975-12-15 1976-06-15 Phenylhydrazinopyridazines
GB1548601A (en) 1976-03-29 1979-07-18 Smith Kline French Lab Pyridazines
JPS5746966A (en) 1980-09-03 1982-03-17 Mitsui Toatsu Chem Inc Pyridazinone derivative and its production
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
EP0051217A1 (en) 1980-10-31 1982-05-12 Usv Pharmaceutical Corporation Oxidation process
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4404203A (en) * 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
HU190412B (en) 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) * 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
JPS58113180A (ja) 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
US4734415A (en) * 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
US4666902A (en) * 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB8323553D0 (en) 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
JPS6087283A (ja) 1983-10-19 1985-05-16 Mitsubishi Chem Ind Ltd ピリダジノン誘導体またはその塩類
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
EP0194548A3 (de) 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB8506319D0 (en) 1985-03-12 1985-04-11 Smith Kline French Lab Chemical compounds
CA1252788A (en) 1985-03-12 1989-04-18 William J. Coates Pyridazinone derivatives
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
JPS63145272A (ja) 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
JPS63154673A (ja) 1986-12-17 1988-06-27 Mitsubishi Kasei Corp ピリタジノン誘導体又はその塩類
US4819929A (en) 1987-02-24 1989-04-11 Stobb, Inc. Apparatus and method for feeding sheets to a sheet gatherer
DE3706427A1 (de) 1987-02-27 1988-09-08 Boehringer Mannheim Gmbh Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel
JPS63215672A (ja) 1987-03-04 1988-09-08 Mitsubishi Kasei Corp ピリダジノン誘導体又はその塩類
DE3728491A1 (de) 1987-08-26 1989-03-09 Heumann Pharma Gmbh & Co Dihydropyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3814057A1 (de) 1988-04-26 1989-11-09 Heumann Pharma Gmbh & Co 6-oxo-pyridazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3826855A1 (de) 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5204463A (en) * 1989-08-10 1993-04-20 Glaxo Inc. Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities
JPH03141264A (ja) * 1989-08-10 1991-06-17 Glaxo Inc 強心活性およびベータ遮断活性を有するピリダジノン
US5053338A (en) * 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
US5531496A (en) * 1994-07-28 1996-07-02 Saturn Corporation Automotive glass enclosure retaining fixture
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
JP3060454B2 (ja) 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
WO2000021935A1 (en) 1998-10-09 2000-04-20 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
KR20010101675A (ko) * 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19918294A1 (de) 1999-04-22 2000-10-26 Bayer Ag O-Aryldithiazoldioxide
DE10010425A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 5-Methyldihydropyridazinone und ihre Verwendung
FI20000577A0 (fi) 2000-03-13 2000-03-13 Orion Yhtymae Oy Pyridatsinyylifenyylihydratsoneja
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
ATE354568T1 (de) 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
CN1469876A (zh) 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
AU2002359376B2 (en) 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
AU2004257025B9 (en) 2003-06-27 2010-05-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
DE102004010194A1 (de) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
EP1833480A2 (en) 2004-11-30 2007-09-19 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
US20080090827A1 (en) 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
CA2602336A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
JP2010013354A (ja) 2006-09-07 2010-01-21 Kyorin Pharmaceut Co Ltd ２−アルキル−６−（ピラゾロピリジン−４−イル）ピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
WO2008058198A1 (en) * 2006-11-07 2008-05-15 Cardiome Pharma Corp. Methods of making compounds having a beta-adrenergic inhibitor and a linker and methods of making compounds having a beta-adrenergic inhibitor, a linker and a phosphodiesterase inhibitor
US20130012485A1 (en) 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
JP2008222580A (ja) 2007-03-09 2008-09-25 Kyorin Pharmaceut Co Ltd ２−置換−５−（ピラゾロピリジン−４−イル）ピラゾロン誘導体及びそれらを有効成分とするホスホジエステラーゼ阻害剤
JP2008222648A (ja) 2007-03-14 2008-09-25 Kyorin Pharmaceut Co Ltd ２−置換−５−（ピラゾロピリジン−３−イル）ピラゾロン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2008239558A (ja) 2007-03-28 2008-10-09 Kyorin Pharmaceut Co Ltd ２−置換−６−（ピラゾロピリジン−３−イル）ピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
BRPI0810330A2 (pt) 2007-05-03 2014-10-14 Cephalon Inc "processo para preparar l-tartarato de (r)-2-metil pirrolidina, processo para preparar 6-{4-[3-((r)-2-metil-pirrolidin-1-il)-propoxi] - fenil}-2h-piridazin-3-ona, processo para preparar d-tartarato de (s)-2-metil pirrolidina"
US7867980B2 (en) * 2007-05-31 2011-01-11 Meiji Seika Kaisha, Ltd. Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
JPWO2008156094A1 (ja) * 2007-06-19 2010-08-26 杏林製薬株式会社 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JPWO2008156102A1 (ja) * 2007-06-19 2010-08-26 杏林製薬株式会社 ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
WO2009082698A1 (en) 2007-12-21 2009-07-02 Abbott Laboratories Compositions for treatment of cognitive disorders
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2250176B1 (en) * 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
EP2752406A1 (en) * 2008-01-30 2014-07-09 Cephalon, Inc. Substituted pyridazine derivatives which have histamine H3 antagonist activity
UA100877C2 (ru) * 2008-01-30 2013-02-11 Сефалон, Інк. Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102439149B (zh) * 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain

Also Published As

Publication number Publication date
NZ574873A (en) 2012-03-30
EA200970156A1 (ru) 2009-08-28
ES2397283T3 (es) 2013-03-06
US20110288075A1 (en) 2011-11-24
UA95644C2 (ru) 2011-08-25
EP2069312A2 (en) 2009-06-17
PT2069312E (pt) 2013-01-24
KR20090031951A (ko) 2009-03-30
JP2009544709A (ja) 2009-12-17
US8247414B2 (en) 2012-08-21
ZA200901336B (en) 2010-06-30
IL196543A0 (en) 2009-11-18
EP2502918A1 (en) 2012-09-26
CN101522638A (zh) 2009-09-02
US8673916B2 (en) 2014-03-18
SI2069312T1 (sl) 2013-03-29
BRPI0713836A2 (pt) 2013-05-28
EA017004B1 (ru) 2012-09-28
US8586588B2 (en) 2013-11-19
IL196543A (en) 2013-09-30
DK2069312T3 (da) 2013-02-04
US20100280007A1 (en) 2010-11-04
MY148634A (en) 2013-05-15
CA2658821A1 (en) 2008-01-31
KR20140037967A (ko) 2014-03-27
RS52626B (sr) 2013-06-28
JP5335675B2 (ja) 2013-11-06
KR101429311B1 (ko) 2014-08-12
EP2069312B1 (en) 2012-11-07
EP2492263A1 (en) 2012-08-29
US8207168B2 (en) 2012-06-26
CA2658821C (en) 2014-10-21
WO2008013838A3 (en) 2008-07-31
AU2007277163B2 (en) 2012-06-21
CA2858816A1 (en) 2008-01-31
HK1134284A1 (en) 2010-04-23
HRP20130044T1 (hr) 2013-02-28
EP2502918B1 (en) 2015-03-25
AU2007277163A1 (en) 2008-01-31
WO2008013838A2 (en) 2008-01-31
US20100273779A1 (en) 2010-10-28
US20140142088A1 (en) 2014-05-22
US20080027041A1 (en) 2008-01-31
MX2009000884A (es) 2009-06-05
PL2069312T3 (pl) 2013-03-29
CN101522638B (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
NO20090628L (no) Pyridizinon derivativater
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20090295L (no) Substituerte heteroarylderivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20071593L (no) Pyrimidinderivater
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20066055L (no) Pyridinderivater
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
UA94129C2 (ru) Соединения для ингибирования митоза
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20081217L (no) Nye benzotiazolonderivater
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application